Therapeutics

Boost to translational medicine in Europe

Next week will mark the launch of the European Infrastructure for Translational Medicine (EATRIS; see go.nature.com/3li8fs). EATRIS aims to help clients (industry, small enterprises, funding organizations and academic institutions) to translate their biomedical discoveries efficiently into preventive, diagnostic or therapeutic products up to the point of clinical proof of concept.

More than 60 leading translational-research centres will make their facilities and expertise available to researchers and industry across Europe, through a single point of entry, bringing together basic scientists and clinicians, as well as public and private partners. These centres may be specialists in, for example, advanced therapies, imaging or biomarkers.

EATRIS will minimize development costs and risks by matching expertise and optimizing the use of academic know-how, infrastructure and patient groups. Quality control, intellectual property and legal frameworks will all be standardized. Rapidly assembled multidisciplinary teams will address each project's specific regulatory and clinical needs.

These measures should also attract much-needed attention to rare and orphan diseases.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Giovanni Migliaccio.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Migliaccio, G., de Man, F. & Ussi, A. Boost to translational medicine in Europe. Nature 497, 565 (2013). https://doi.org/10.1038/497565c

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.